Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Role of NK cells in immune escape in patients with classical paroxysmal nocturnal hemoglobinuria

Chaomeng Wang, Yan Yang, Wei Wang et al. Nov 03, 2025 pp. 4664-4664 10.1182/blood-2025-4664

Abstract Abstract Background: Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematopoietic stem cell disorder. Immune escap...

Clinical benefit of luspatercept in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with early disease characteristics and very low-, low-, or intermediate-risk Myelodysplastic Syndromes (LR-MDS): A post hoc analysis from the commands trial

Valeria Santini, Matteo Della Porta, Rami Komrokji et al. Nov 03, 2025 pp. 792-792 10.1182/blood-2025-792

Abstract Background: In the phase 3 COMMANDS trial (NCT03682536) evaluating pts with ESA-naive transfusion-dependent (TD...

Redefining the myeloid disease continuum: Machine learning–based development and validation of an integrated multimodal classification of myeloid neoplasms

Yu-Hung Wang, Kristian Gurashi, Chien-Chin Lin et al. Nov 03, 2025 pp. 4347-4347 10.1182/blood-2025-4347

Abstract Introduction The 2022 WHO/ICC classifications of myeloid neoplasms (MNs) incorporated genomics into the existing clinicopathologic...

Piezo1-mediated mechanosensation in bone marrow macrophages promotes  hematopoietic support function of BM-MSCs in a CD105-dependent manner

Huihui Fu, Liuyue Zhai, Yao Liu et al. Nov 03, 2025 pp. 4962-4962 10.1182/blood-2025-4962

Abstract Background: Hematopoietic reconstitution following high-dose radiotherapy and chemotherapy is closely regulated by the hematopoieti...

From efficacy to experience: 52-week patient-reported outcomes with Mim8 in adolescents and adults with hemophilia A with or without inhibitors (FRONTIER2)

Cedric Hermans, Sanjay Ahuja, Hazza Alzahrani et al. Nov 03, 2025 pp. 540-540 10.1182/blood-2025-540

Abstract Introduction Mim8 is a new-generation, bispecific antibody, activated factor VIII mimetic in clinical developme...

Deep learning enables automated quantification of hematopoietic stem and progenitor cells (HSPCs) in zebrafish embryos

Xavier Vesco, Konur Oyman, Annika Chura et al. Nov 03, 2025 pp. 6112-6112 10.1182/blood-2025-6112

Abstract Acute myeloid leukemia (AML) is a malignancy of hematopoietic stem and progenitor cells (HSPCs), characterized by the unchecked pro...

Phase II study of polatuzumab in combination with chemoimmunotherapy for richter transformation (PolaR-EPCH).

John Allan, Andrew Lipsky, Seema Bhat et al. Nov 03, 2025 pp. 3681-3681 10.1182/blood-2025-3681

Abstract Background: Richter transformation (RT) is a rare complication observed in patients (pts) with chronic lymphocytic leukemia/small l...

“efficacy and safety of treosulfan- vs. busulfan-based conditioning regimens in adult allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes and acute myeloid leukemia: A systematic review and meta-analysis.”

Muhammad Shaheer Bin Faheem, FNU Sawaira, Sai Sushrutha Mudupula Vemula et al. Nov 03, 2025 pp. 6991-6991 10.1182/blood-2025-6991

Abstract Background: Treosulfan has emerged as a potentially less toxic alternative to busulfan in conditioning regimens for allogeneic hema...

The single-cell transcriptomic dissection analysis: Platelet-t cell/macrophage crosstalk and immune imbalance in aplastic anemia (AA)

Shuai Tan, Fang Fang, Jing Sun et al. Nov 03, 2025 pp. 6723-6723 10.1182/blood-2025-6723

Abstract Background the pathogenesis of HSPCs impairment in aplastic anemia (AA) remains unclear. In this study, in addition to focusing on C...

The fanconi anemia pathway restrains MLL-rearranged leukemogenesis through suppressing NHEJ-mediated genomic instability

Jian Xu, Logan Sund, Emily Wolff et al. Nov 03, 2025 pp. 1502-1502 10.1182/blood-2025-1502

Abstract Genetic rearrangements involving the mixed lineage leukemia (MLL) gene give rise to MLL-rearranged (MLL-r) leukemia, which compromi...

Bendamustine, gemcitabine, and vinorelbine (BeGEV) regimen followed by ASCT Induces Durable Remissions in PD-(L)1 inhibitor-resistant Refractory/relapsed classical Hodgkin lymphoma: A single-center, long-term study

Xingchen Liu, Qing Zhang, Hao Guo et al. Nov 03, 2025 pp. 1847-1847 10.1182/blood-2025-1847

Abstract Background Primary refractory or relapsed disease occurs in 20–40% of classical Hodgkin lymphoma (cHL) patients after first-line th...

Correlative data from an ongoing Phase 1, multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK cell therapy for Acute Myeloid Leukemia (AML) is consistent with its clinical activity and unique logic gated mechanism of action

Muharrem Muftuoglu, Enping Hong, Nosha Farhadfar et al. Nov 03, 2025 pp. 5921-5921 10.1182/blood-2025-5921

Abstract SENTI-202 is being evaluated in an ongoing Phase I clinical trial, SENTI-202-101 (NCT06325748). SENTI-202 selectively kills AML bla...

Acute Myeloid Leukemia-associated pneumonia mortality trends (1999–2023) and ARIMA-based projections through 2050 in geriatric u.S. adults

Haseeb Tareen, Allah Dad, Muhammad Arham et al. Nov 03, 2025 pp. 6932-6932 10.1182/blood-2025-6932

Abstract Introduction: Pneumonia is a prevalent and serious complication in acute myeloid leukemia (AML), affecting more than 25% of treated...

Application of machine learning to identify risk factors for 14-day emergency department return visits in pediatric sickle cell patients discharged after vaso-occlusive crises

Kenneth McKinley, Muhammad Rahman, Deepika Darbari et al. Nov 03, 2025 pp. 7893-7893 10.1182/blood-2025-7893

Abstract Sickle cell disease (SCD) is a severe, chronic disease associated with frequent vaso-occlusive crises (VOC), leading to extreme pai...

Rethinking ferritin reference ranges for diagnosing iron deficiency at Denver health

Megan Connor, Nosakhare Osazuwa, Omar Shbeeb et al. Nov 03, 2025 pp. 4393-4393 10.1182/blood-2025-4393

Abstract Introduction Iron deficiency (ID) is a globally burdensome, yet highly treatable disease, affecting 2 billion total people worldwid...

Real-world outcomes of teclistamab for multiple myeloma in Canada: Multi-institutional report from the Canadian myeloma research group (CMRG) database

Guido Lancman, Donna Reece, Arleigh McCurdy et al. Nov 03, 2025 pp. 7596-7596 10.1182/blood-2025-7596

Abstract Introduction: Teclistamab is a highly effective treatment for relapsed multiple myeloma (MM), with an overall response rate (ORR) o...

Phase IB/II trial of epcoritamab plus ibrutinib in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Yazeed Sawalha, Marie Hu, Rina Welkie et al. Nov 03, 2025 pp. 8239-8239 10.1182/blood-2025-8239

Abstract Background: The CD3xCD20 bispecific antibody epcoritamab has shown significant clinical activity in relapsed/refractory large B-cel...

In severely injured civilian trauma patients, preemptive transfusion of low-titer group o+ non-leukoreduced whole blood promotes significantly improved 30-day survival

Eldad Dann, Tania Mashiach, Basel Darawshew et al. Nov 03, 2025 pp. 3144-3144 10.1182/blood-2025-3144

Abstract Introduction: Trauma is a major cause of death worldwide; yet, patients (pts) with traumatic hemorrhage are potentially salvageable...

Examining the utility of RBC transfusions in uncomplicated vaso-occlusive episodes

Matthew Nguyen, Benjamin W. Friedman, Cheryl Tung et al. Nov 03, 2025 pp. 1161-1161 10.1182/blood-2025-1161

Abstract Vaso-occlusive episodes (VOE) are the leading cause of in-patient admissions in sickle cell disease (SCD). While RBC transfusions a...

Glp-1 receptor agonist use is associated with lower risk of progression from MGUS to SMM or MM in a large real-world cohort

Arooj Abidi, Hashim Mann, Sneha Purvey et al. Nov 03, 2025 pp. 404-404 10.1182/blood-2025-404

Abstract Background: Monoclonal gammopathy of undetermined significance (MGUS) is a precursor to multiple myeloma (MM) and smoldering multip...

Zanubrutinib combined with intrathecal chemotherapy for prevention of CNS relapse in high-risk diffuse large B-cell lymphoma

Fengping Zhou, Shenhe Jin, Feiteng Huang et al. Nov 03, 2025 pp. 5464-5464 10.1182/blood-2025-5464

Abstract Background: Secondary central nervous system lymphoma (SCNSL) in diffuse large B-cell lymphoma (DLBCL) carries...

Respiratory syncytial virus (RSV) infection in adults with blood cancer: An England-wide population study

Yeong Jer Lim, Temitope Erinfolami, Nurunnahar Akter et al. Nov 03, 2025 pp. 6402-6402 10.1182/blood-2025-6402

Abstract Background The recent development of vaccines for respiratory syncytial virus (RSV) has created a pressing need to better quantify...

Outcomes of adolescent and young adult patients with AML treated on adult versus pediatric protocols

Ira Kraft, Venkata Preetam Sandeep Kaduluri, Kelsey Pandrangi et al. Nov 03, 2025 pp. 2832-2832 10.1182/blood-2025-2832

Abstract Background: Acute Myeloid Leukemia (AML) treatment in adolescent and young adult (AYA) patients (pts) may be challenging due to the...

Phase 1 assessment of novel transposon BAFF CAR-T cells (LMY-920) for non-Hodgkin lymphoma (NHL) and multiple myeloma (MM)

Paolo Caimi, Leland Metheny, Matthew Spear et al. Nov 03, 2025 pp. 1954-1954 10.1182/blood-2025-1954

Abstract Background and Significance: Marked success has been achieved using scFv-based CAR-T cell therapies targeting CD19 and BCMA to trea...

Artificial intelligence (AI)–based membrane specific PD-L1 and immune subtypes as predictive biomarkers for danburstotug in relapsed or refractory extranodal NK/T cell lymphoma (R/R ENKTL): Insights from the Phase II trial (DISTINKT)

Won Seog Kim, Seok Jin Kim, Jae-Cheol Cho et al. Nov 03, 2025 pp. 5426-5426 10.1182/blood-2025-5426

Abstract Introduction: Danburstotug has demonstrated promising efficacy in patients with R/R ENKTL. However, the relationship between PD-L1...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page